Pretzel Therapeutics presents PX578 data supporting POLG disease treatment
Pretzel Therapeutics has unveiled promising preclinical data for its investigational therapy PX578, presented at the 2026 MDA Clinical and Scientific Conference. This first-in-class small molecule targets mitochondrial DNA depletion syndromes, particularly POLG disease, a rare genetic condition lacking approved disease-modifying treatments. PX578 activates mitochondrial DNA polymerase gamma (POLG) to address the root cause of these disorders by enhancing mitochondrial DNA levels.
The significance of this development lies in its potential to transform treatment for patients with POLG disease, which affects energy production and manifests through severe neurological and metabolic symptoms. Preclinical studies indicate that PX578 not only boosts mitochondrial DNA levels but also improves cellular respiration and energy production, with positive outcomes observed across various POLG mutations affecting about 70% of patients.
As Pretzel Therapeutics moves forward with a Phase 1 clinical study and plans for a Phase 2 trial, the implications for therapeutic strategies in mitochondrial dysfunction are substantial. For a deeper dive into these findings, I recommend checking out the full article.